Thomas Bogenrieder

A physician-scientist (MD and PhD) by background and an academic expertise in melanoma skin cancer and other oncology areas, Thomas Bogenrieder has almost 30 years of experience in academic research (molecular biology and immunology), clinic (dermatology and clinical immunology) and clinical development in the biopharmaceutical industry and has worked in the biopharmaceutical industry for more than 17 years, holding positions in oncology drug development (e.g. Lapatinib, Dabrafenib, Trametinib, Xentuzumab) and medical affairs at GlaxoSmithKline (GSK) and Boehringer Ingelheim, encompassing assignments in Germany, Europe and at a global level. As such, he gained extensive international experience in global drug development in oncology from first in humans to registration, including strategic, medical-scientific, translational, regulatory, drug safety, data management, and operational aspects.

He qualified in Medicine at the Albert-Ludwigs-University, Freiburg (Germany), after studying medicine in Homburg/Saar (Germany) and at Louis Pasteur University Strasbourg (France). Thomas completed a post-doctoral fellowship in molecular cancer biology at Memorial Sloan-Kettering Cancer Center in New York and worked as a visiting scientist at the Wistar Institute in Philadelphia. Moreover, he holds a PhD in “Clinicopathological and Molecular Aspects of Cutaneous Melanoma” from the University of Utrecht (The Netherlands). He’s board-certified and practiced Dermatology and Clinical Immunology at the University of Regensburg and in private practice in Germany before entering the Biopharmaceutical Industry.

Thomas has an outstanding track record: he helped 5 companies to get compounds into phase 1 clinical development; 4 of which floated successfully or were acquired by a big pharma company.